Credit: Cincinnati Children's
PET-CT images of a 10-month-old child with Langerhans cell histiocytosis (LCH) show increased disease activity in the bones (left image). Three months after the start of oral therapy with the drug dabrafenib, the image on the right shows near complete resolution of disease activity. The child was part of a study in JCI Insight from Cincinnati Children’s summarizing outcomes of off-label oral therapy in patients with histiocytoses that were resistant to chemotherapy. Study authors recommend additional study, including clinical trials to further test the therapeutic approach.